Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OKYO | US
0.02
1.26%
Healthcare
Biotechnology
30/06/2023
24/04/2026
1.61
1.57
1.64
1.57
OKYO Pharma Limited a preclinical biopharmaceutical company engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201 a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London the United Kingdom.
View LessLow Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
57.9%1 month
54.7%3 months
67.2%6 months
90.6%-
-
14.11
-1.08
0.43
-4.29
-
-
-15.75M
54.48M
54.48M
-
-
-
-
-2.97K
5.77
0.86
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.24
Range1M
0.28
Range3M
1.05
Rel. volume
0.33
Price X volume
49.50K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.91 | 59.16M | 1.06% | n/a | 1.95% |
| QNCX | QNCX | Biotechnology | 1.36 | 58.86M | 0.00% | n/a | 30.62% |
| CDIO | CDIO | Biotechnology | 1.82 | 55.69M | 0.00% | n/a | 28.31% |
| Rani Therapeutics Holdings Inc. Class A Common Stock | RANI | Biotechnology | 0.9389 | 54.33M | 2.56% | n/a | 1243.32% |
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.8 | 52.37M | 10.34% | n/a | 118.63% |
| 22nd Century Group Inc | XXII | Biotechnology | 1.66 | 52.18M | -2.92% | n/a | -1072.15% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 1.28 | 51.37M | 1.59% | n/a | 2.71% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.97 | 50.30M | 4.23% | n/a | 6.85% |
| PEPG | PEPG | Biotechnology | 1.54 | 50.19M | -3.14% | n/a | 12.52% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 14.3 | 48.75M | 2.36% | n/a | 3.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.29 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 14.11 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 67.19 | 72.80 | Par |
| Debt to Equity | -1.08 | -1.23 | Cheaper |
| Debt to Assets | 0.43 | 0.25 | Expensive |
| Market Cap | 54.48M | 3.66B | Emerging |